Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized study of CS-7017 as maintenance therapy in colorectal cancer after first-line chemotherapy
2008-005848-16Phase 2Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in colorectal cancer (CRC) comparing CS-7017 maintenance with Placebo maintenance (2 arms). Primary endpoint: Progression-free survival rate at 18 weeks. Started Apr 2009; status: terminated.
02
Drugs
efatutazone
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2008-005848-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005848-16.